Investors > Media > 2012 Press Releases
"Our mission is to translate science from the lab to the clinic to the market."
—EVP Menghis Bairu
2012 Press Releases
 |
|
26 January 2012
ASCEND Study to Evaluate the Effectiveness of TYSABRI® (natalizumab) as a Treatment for Secondary-Progressive Multiple Sclerosis| WESTON, Mass. & DUBLIN--(BUSINESS WIRE)--Jan. 26, 2012--
Biogen
Idec (NASDAQ: BIIB) and Elan
Corporation, plc (NYSE: ELN) today announced a global Phase 3b
study, ASCEND, that is being conducted to evaluate the effectiveness of
TYSABRI as a treatment for secondary-progressive multiple sclerosis
(SPMS). According to the National Multiple Sclerosis Society,
approximately half of all people initially diagnosed with
relapsing-remitting mult... |
|
25 January 2012
Elan Announces Webcast of Fourth Quarter and Full-Year 2011 Financial Results| DUBLIN--(BUSINESS WIRE)--Jan. 25, 2012-- Elan Corporation, plc (NYSE:ELN) announced today that it will host a conference call on Wednesday, February 8, 2012 at 8:30 a.m. Eastern Standard Time (EST), 1:30 p.m. Greenwich Mean Time (GMT) with the investment community to discuss Elan’s fourth quarter and full-year 2011 financial results, which will be released before the European and U.S. financial markets open.
Live audio of the conference call will be simultaneously broadcast over the Internet a... |
|
20 January 2012
FDA Updates TYSABRI® (natalizumab) Label to Include Anti-JC Virus Antibody Status as a PML Risk Factor| WESTON, Mass. & DUBLIN--(BUSINESS WIRE)--Jan. 20, 2012-- Today Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) announced that the U.S. Food and Drug Administration (FDA) has approved a product label change for TYSABRI that will help enable individual benefit risk assessment for patients with multiple sclerosis (MS). The new label identifies anti-JCV antibody status as a risk factor for developing an infrequent but serious brain infection known as progressive multifocal leukoence... |
|
|
RSS Feeds | 
E-mail Alerts | 
Contact IR